Alcon agreed to buy LENSAR for $14.00/share cash, integrating ALLY, Streamline, and the legacy laser system to expand FLACS ...
Their Perspective article, published in npj Digital Medicine, warns that treating medical artificial intelligence (AI) as an ...
NovaBridge Biosciences and Visara have announced topline results from their phase 2a study of VIS-101 for retinal vascular ...
ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...
Commercial rollout includes direct purchasing and specialty distribution, alongside scaled investments in awareness, ...
Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...
Physiologic AL varies materially with age, sex, height, and ethnicity, undermining fixed AL thresholds as broadly applicable risk stratifiers in typical pediatric myopia. Retinal pathology risk ...
The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...
Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...
Management prioritizes 5%–10% weight loss and acetazolamide titration guided by Frisén grading, OCT, and visual fields; ...
Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring ...
MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results